Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

Exclusion criteria

• . Patients with non-plaque form of psoriasis (erythrodermic, guttate, pustular or palmo plantar psoriasis; severe form of psoriasis arthritis, inverse form of psoriasis). Mild to moderate cases of psoriasis arthritis are allowed provided there is no impact on study objectives as determined by the Investigator.
• . Patients with drug-induced psoriasis.
• . Evidence of skin conditions at the time of screening visit other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
• . Patients with any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form.
• . Pregnant or lactating females or females planning to become pregnant during the study and/or within 28 days following the last dose of study medication.
• . Male patients planning a partner pregnancy or sperm donation during the study or within 3 months following the last dose of study medication.
• . Known allergies to mannitol, macrophage modulators, and gelatin.
• . Patients with a recent history or current signs or symptoms, as determined by the Investigator, of severe, progressive viral or bacterial infections, of clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic insufficiency disease (excluding psoriasis) requiring systemic treatment or other major diseases, which are not well controlled and may interfere with the conduct of the trial.

Pharmacokinetics (PK) - Time

Timeframe: Study Day 1